stockrowVericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024.
- Revenue
- +26.5%
- EPS
- +180.0%
- Free cash flow
- −19.4%
Quarter to September 2026, against a year earlier
Follow VCEL
Alert me
Vericel Corporation (VCEL) EBITDA
Vericel Corporation's EBITDA for fiscal 2025 was $22.6M, up 136.1% from $9.6M in fiscal 2024. Over the twelve months to 30 June 2026 it was $31.3M. Over the past ten years it has ranged from −$15.1M (fiscal 2015) to $22.6M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 3 consecutive fiscal years. Vericel Corporation ranks 40th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $22.6M | 136.09% |
| FY2024 | $9.6M | — |
| FY2023 | −$2.4M | — |
| FY2022 | −$12.9M | — |
| FY2021 | −$3.9M | — |
| FY2020 | $5.1M | — |
| FY2019 | −$10.1M | — |
| FY2018 | −$2.8M | — |
| FY2017 | −$13.4M | — |
| FY2016 | −$14.7M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $4.1M | — |
| Mar 2026 | −$4.8M | — |
| Dec 2025 | $25.6M | 301.69% |
| Sep 2025 | $6.4M | 699.12% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ADMA ADMA Biologics Inc compare | $232.8M |
| AUPH Aurinia Pharmaceuticals Inc compare | $163.4M |
| VCEL Vericel Corporation | $31.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$57.7M |
| PHVS Pharvaris N.V. compare | −$212.2M |
| IMNM Immunome, Inc. compare | −$268.3M |
| CLDX Celldex Therapeutics, Inc. compare | −$326.7M |
| VERA Vera Therapeutics, Inc. compare | −$417.0M |
| BHVN Biohaven Ltd. compare | −$515.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on VCEL
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement